Searched for
SEMAGLUTIDE COMPETITORS
Novo Nordisk plans to cut price of Ozempic as generics hit marketNovo Nordisk is set to lower the price of its popular weight loss and diabetes drug, Ozempic. This move comes after several Indian drugmake...- Natco beats rivals with Rs 1,290 semaglutide launch as Novo Nordisk patent expiresNatco Pharma introduces a new, affordable semaglutide injection in multidose vials. This launch coincides with the patent expiry of the inn...
- Eli Lilly sticks to premium pricing for its innovator drug ahead of generics waveEli Lilly remains optimistic about strong demand for its weight-loss and anti-diabetes injectable, tirzepatide (sold as Mounjaro), despite ...
- Liraglutide still a ‘decent market’ despite Novo’s price moves: Siddharth Mittal, BioconBiocon CEO Siddharth Mittal outlines the company's strategy in the competitive GLP-1 market. Focusing on liraglutide's launch in the US and...
- Biocon in very unique position globally as a biosimilars leader: Kiran Mazumdar-ShawBiocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...
- Patent expiry looms: Eli Lilly and Novo Nordisk strategise to defend their top obesity drugs in IndiaAt a recent industry summit, executives from Eli Lilly and Novo Nordisk unveiled their game plan for tackling weight-loss medications in In...
- What’s powering Mounjaro’s rise to the top of Indian drug marketMounjaro has made a splash in Indian healthcare, emerging as the go-to solution for both diabetes management and weight loss. This remarkab...
- Dr Reddy’s Laboratories shares fall over 1% on Q2 results. Should you buy, sell or hold?Despite an uptick in profits, Dr Reddy's Laboratories experienced a decline in share value. Analysts continue to express optimism, keeping ...
- Is Novo Nordisk facing its “Nokia moment”? Stock tumbles to $50 from a year-high of $139 amid disruptive rivals and shifting market forcesNovo Nordisk’s stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, and legal ch...
- Domestic drug companies in a sweet spot as global players look beyond insulinIndian drug cos are increasing their presence in the insulin market. They are competing with multinational corporations. Affordable insulin...
- Maker of Wegovy, Ozempic showers money on US obesity doctorsNovo Nordisk, a Danish pharmaceutical company renowned for its diabetes medicines, is now positioning itself as the world's leading weight-...
Load More
